Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

In this study, D-004 did not affect androgen-dependent development in rats exposed in utero, while finasteride caused significant changes in male offspring's androgen-dependent tissues.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

Finasteride reduces prostate size and symptoms with few side effects.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

Finasteride may cause breast enlargement, low testosterone a risk factor.

This study explored the effects of a 50% hydroalcoholic UPBF extract on BPH in testosterone propionate-induced rats, finding significant improvements in prostate-related parameters and lower urinary tract symptoms at a 200 mg/kg dose, suggesting potential use in BPH management.

This study identified Aquilaria sinensis and Piper cubeba as tropical plants with potential anti-androgenic and anti-estrogenic properties that could help prevent or alleviate benign prostatic hyperplasia and prostate cancer.

A new compound that could treat various androgen-related conditions was created and analyzed.

This study found that unripe Rubus occidentalis extracts may inhibit benign prostatic hyperplasia development in a rat model by reducing prostate weight and androgen-related gene expression.

A new compound was made that might help treat diseases related to male hormones.

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

In this study, men using finasteride-1 mg long-term for androgenic alopecia were more likely to receive PDE5i prescriptions sooner than non-users, while also having reduced rates of elevated PSA and prostate cancer diagnoses.

This study found that olive leaves extract significantly decreased prostate index, serum PSA, testosterone, and DHT levels in male rats with testosterone-induced benign prostatic hyperplasia, and showed potential as a therapeutic option due to its positive effects on prostate histology and antioxidant activity.

In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.

This study reports that structural and biochemical analysis of steroid 5α-reductases clarifies how they mediate steroid reduction with NADPH, potentially aiding in designing targeted therapies.

This study found that methanol extract from Sapium rotundifolium Hemsl. reduced prostate enlargement and related protein expressions in testosterone-induced benign prostatic hyperplasia models in both cells and rats.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

This study concludes that the accuracy of PSA testing for prostate cancer diagnosis is not only maintained but may be increased when used alongside 5-alpha reductase inhibitors like finasteride and dutasteride.

This study calculated the molecular properties of finasteride using PM3 methods, providing insights into its characteristics despite the lack of published data on these properties.

This study found that finasteride administration for more than one month before TURP surgery significantly reduces blood loss in patients with benign prostatic hyperplasia.